This HTML5 document contains 149 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q45236388
rdf:type
wikibase:Item
schema:description
artigo científico teaduslik artikkel 2005年學術文章 article scientific 2005年学术文章 tudományos cikk wetenschappelijk artikel scientific article published in January 2005 επιστημονικό άρθρο научная статья vitenskapelig artikkel научни чланак 2005년 논문 2005年学术文章 vedecký článok 2005年學術文章 scientific article published in January 2005 мақолаи илмӣ article científic জানুয়ারি ২০০৫-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ bài báo khoa học videnskabelig artikel artikel ilmiah научна статия naučni članak наукова стаття, опублікована в січні 2005 artikulong pang-agham מאמר מדעי 2005年学术文章 2005年学术文章 articol științific article scientifique 2005年學術文章 مقالة علمية نشرت في يناير 2005 artigo científico wissenschaftlicher Artikel artículo científico publicado en 2005 2005 nî lūn-bûn tieteellinen artikkeli บทความทางวิทยาศาสตร์ bilimsel makale სამეცნიერო სტატია scienca artikolo vitskapeleg artikkel 2005年學術文章 artykuł naukowy 2005年学术文章 artikull shkencor 2005年の論文 vetenskaplig artikel articolo scientifico artículu científicu научни чланак scientific article published in January 2005 2005年學術文章 2005年学术文章 vědecký článek artigo científico
p:P577
wds:Q45236388-53610C72-04E2-412B-A645-862D903ABB54
wdt:P577
2005-01-01T00:00:00Z
p:P407
wds:Q45236388-D5DC04E5-8CA4-40A1-9E55-BAC044E580EE
wdt:P407
wd:Q1860
p:P2860
wds:Q45236388-080DA944-FAA1-47CF-9463-C246323AC307 wds:Q45236388-083AA100-BBD7-4731-A050-02367B2454D8 wds:Q45236388-0D30141C-F175-428D-9030-7B2761A0AE4E wds:Q45236388-1929DE46-D72C-4387-95BB-2FC6ABE5DFCD wds:Q45236388-EFA91806-2C48-471A-88F8-66B2ACB1E547 wds:Q45236388-BA19DBC3-7949-4F52-AFFF-03694F03A1E7 wds:Q45236388-BC8EA486-57B4-4CC4-AE68-2DA4A89F688F wds:Q45236388-BFE581C8-E42A-4B58-9591-95BFB8F91F21 wds:Q45236388-D8B29E87-0138-408C-98F1-4C6F9BEE89D1 wds:Q45236388-E0216912-7FD7-444E-B8EA-18F86B5F9F95 wds:Q45236388-E6531252-6978-4A0A-8326-39F9DD8870F8 wds:Q45236388-EBEB02F2-3C7E-497A-8BF3-93CBE0F0CEEF wds:Q45236388-93A844B0-EE6C-45D5-AE0A-5E25FF98BD83 wds:Q45236388-9E2E84FB-8D91-412F-A282-CDD384AB048B wds:Q45236388-A575D975-317C-42A6-9937-7CC7B7FA61F9 wds:Q45236388-AE4C8D12-A7B2-4116-B010-3FB3E5AB7282 wds:Q45236388-B1F87141-CAE1-40D3-90FA-11754EDB877A wds:Q45236388-7E64CE28-36D1-4DD8-B32D-BA916A062B52 wds:Q45236388-364ABFE3-E09E-4FA4-A384-35A4821EB829
wdt:P2860
wd:Q72078080 wd:Q35553616 wd:Q60156373 wd:Q43784087 wd:Q43937942 wd:Q39413134 wd:Q34856489 wd:Q43784091 wd:Q34758712 wd:Q34422623 wd:Q44611369 wd:Q44938460 wd:Q44971706 wd:Q34152748 wd:Q29620070 wd:Q48318693 wd:Q41468633 wd:Q43594181 wd:Q33767866
p:P2093
wds:Q45236388-88F4C8FF-8E40-4DE6-AD16-014C5A503AFF wds:Q45236388-492DED71-A555-4F57-87AD-93A3981E28ED wds:Q45236388-45D54976-17A5-48BA-BE4D-D0A99193021D wds:Q45236388-97D46309-656B-4091-847E-10031079B150 wds:Q45236388-9B04A7E7-B436-488E-8B19-06228F822059 wds:Q45236388-FA4CAFF5-DE46-45D5-914D-2768C44D19FC wds:Q45236388-F6BDA156-41DE-4B51-B275-2FD0F719E634
wdt:P2093
E Efstathiou A Kostakopoulos C Deliveliotis A Bamias C Papadimitriou N Antoniou D Skarlos
rdfs:label
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment
skos:prefLabel
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment
schema:name
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment
p:P50
wds:Q45236388-FB421493-72EC-4371-9189-0827C6FD2764 wds:Q45236388-0577E6D6-CBCA-4A15-BDC0-4C8332BC652A wds:Q45236388-3149B286-9FB4-49A7-A02F-E4FD9120F7A3
wdt:P50
wd:Q26338766 wd:Q43281148 wd:Q43187559
p:P1476
wds:Q45236388-919E9B66-745F-4786-BF2D-E0B0D6ABCA83
wdt:P1476
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment
p:P304
wds:Q45236388-50E0C662-498F-4C48-99D4-BC29E3EB9FB5
wdt:P304
126-130
p:P31
wds:Q45236388-8B7CEF79-25D9-4A20-B3D8-DFBE333ED88C
wdt:P31
wd:Q13442814
p:P921
wds:Q45236388-9094B13C-669E-4C84-A7E3-B2E69CA5DA71 wds:Q45236388-7C31AD54-C73A-4BB9-BCF6-83FA3BD609E0
wdt:P921
wd:Q218507 wd:Q420436
p:P698
wds:Q45236388-5B2BCC9D-CE28-47CA-B11D-71D135D69995
wdtn:P698
n11:15667877
wdt:P698
15667877
p:P1433
wds:Q45236388-5A46A65B-B5E6-408A-945C-C9CE0A1F1B99
wdt:P1433
wd:Q7900884
p:P433
wds:Q45236388-3F0295E9-559B-40BD-9953-FE490967D3B0
p:P478
wds:Q45236388-642018D2-BDF5-4F4F-B0E7-CC32C7F594E9
wdt:P433
1
wdt:P478
65
p:P356
wds:Q45236388-4DD38764-B49E-4C18-A111-72FB102F3AF8
wdtn:P356
n12:J.UROLOGY.2004.08.041
wdt:P356
10.1016/J.UROLOGY.2004.08.041